Abstract The pharmacokinetics of oral dexniguldipine, a new multidrug-resistance-modifying agent under clinical evaluation, and its pyridine metabolite M-1 were determined in plasma, tumor, and renal tissue in Wag/ Rij rats bearing a multidrug-resistant CC531 colon adenocarcinoma tumor under the renal capsule. The pharmacokinetics were studied in four experiments. After a single administration of dexniguldipine (30 mg/ kg), tumors and kidneys were collected after 5 (experiment 1), 24 (experiment 2), and 48 h (experiment 3). In the fourth experiment, dexniguldipine was given once daily for 3 consecutive days at a dose of 30 mg/kg. In all experiments, plasma samples were collected at regular intervals. The concentrations of dexniguldipine and M-1 could be determined in plasma in most of the rats at up to 32 h after drug administration. The area under the curve (AUC) of dexniguldipine and M-1 varied by a factor of 2±6 in the four experiments. High tumortissue concentrations of dexniguldipine were observed. The concentrations were highest in the multiple-dose experiment (2014 1005 ng/g tissue). High degrees of correlation (>0.8) were established between the concentrations of dexniguldipine measured in plasma and tumor as well as renal tissue. Overall, tumor-tissue concentrations of M-1 comprised one-third of the dexniguldipine concentrations measured.
Introduction
Dexniguldipine is the (A) enantiomer of niguldipine, a dihydropyridine derivative. In in vitro studies, dexniguldipine has been found to bind to P-glycoprotein (P-gp) and to enhance the cytotoxicity of chemotherapeutic agents such as doxorubicin and etoposide in several cell lines resistant to these agents [3±5] . The synergistic eect may well be associated with reversal of multidrug resistance (MDR) related to the activity of P-gp. Also, the pyridine metabolite M-1 has demonstrated pharmacologic activity [3±5, 8] . Dexniguldipine is extensively metabolized by the cytochrome P450 system and, most likely, by CYP (CYP 3A).
In addition, other in vitro studies have revealed that dexniguldipine itself has potent and selective cytotoxic activity against several tumor cell lines. The mechanism of cytotoxic action has not been fully elucidated, but interaction with protein kinase C and other parts of the intracellular signal-transduction pathway have been proposed [2, 12] .
Many MDR-modifying agents have been applied in the clinic, such as verapamil, cyclosporin A, quinidine, and tamoxifen, among others [9, 11, 13] . The results obtained with verapamil have revealed serious cardiovascular side eects at levels of exposure that are presumably insucient to achieve MDR reversal [10] . In addition, the lack of information about tumor-tissue concentrations of the MDR modi®er has limited the optimal design of clinical studies with an MDR modi®er and a P-gp-dependent anticancer agent [6, 17] . The af®nity of dexniguldipine for the calcium-channel receptor site is relatively low. This enables clinical administration of high doses of the drug. However, the resulting concentration range of the drug in tumor tissues has not been established. At present, dexniguldipine in combination with anticancer agents is undergoing phase I/II clinical testing, for example, in small-cell lung cancer.
The aim of the present study was to explore the pharmacokinetics of dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of Wag/Rij rats bearing an intrinsic MDR CC531 colon adenocarcinoma as a solid tumor under the renal capsule [1, 15] .
Materials and methods
Experiments were approved by the Animals Ethics Board of the University of Rotterdam.
Assay of dexniguldipine and M-1 in plasma, tumor, and renal tissue
Apparatus
Dexniguldipine and M-1 were determined in plasma, tumor, and renal tissue using an automated reverse-phase isocratic high-performance liquid chromatography (HPLC) assay with UV detection at 230 nm. A model 710B WISP autosampler and a model M510 pump were used (Waters Associates, Milford, Mess. USA). The detector was a UV2000 device (Spectra Physics, San Jose, Calif. USA). The data were processed with a Shimadzu CR3A integrator (Shimadzu Corporation, Kyoto, Japan). The column was a Shandon Hypersyl CPS column (3 lm, 150´4.6 mm; LC Service, Emmen, The Netherlands). The eluent consisted of 5 mM phosphate buer (pH 7.5) with 60% acetonitrile. The¯ow rate was 1.5 ml/min and the column temperature was 40°C. A volume of 100 ll was injected into the HPLC system.
Chemicals
Dexniguldipine hydrochloride (B8509-035, batch 292-349), metabolite M-1 {B8909-008, batch U1 29/071; chemical name 3-acetyl-2,6-dimethyl-4-nitrophenyl-5-[5-(4,4-diphenyl-1-piperidinyl)-pentanoyl] pyridine fumarate}, and the internal standard for the assay (B 9003-001, batch Zi 04/106) were obtained from Byk Gulden (Konstanz, Germany). All other chemicals were obtained from Baker (Deventer, The Netherlands) and were of analytical grade.
Plasma-sample preparation
A volume of 150 ll plasma was collected, to which 50 ll of a 2000-ng/ml solution of internal standard (B 9003-001, batch Zi 04/106) in methanol was added. A volume of 800 ll deionized Milli-Q water was added, and the solution was mixed on a whirl mixer for 15 s. For extraction a volume of 7 ml dichloromethane (DCM)/ hexane/isobutylalcohol (40:60:0.5, by vol.) was added. The liquid was mixed for 30 min on a whirl mixer and subsequently centrifuged for 5 min at 4000 g. The organic layer was collected and evaporated to dryness at 50°C under vacuum. The residue was reconstituted in 150 ll eluent. Calibration curves were constructed at up to 2000 ng/ml. The recovery of dexniguldipine, M-1, and the internal standard was determined relative to the direct injection of the individual dissolved compounds.
Tumor-tissue extraction
Tumor tissue was homogenized with a Turrax homogenizer (Boom, Meppel) in 1 ml Milli-Q water. The Turrax was¯ushed twice with 250 ll Milli-Q water. A 50-ll volume of a 2000-ng/ml internal standard solution in methanol was added. Subsequently, a 7-ml volume of DCM/hexane/isobutylalcohol (40:60:0.5 by vol.) was added and the mixture was vortexed for 30 min. Thereafter the mixture was centrifuged for 5 min at 4000 g. The organic layer was collected and evaporated to dryness at 50°C under vacuum. The residue was reconstituted in 150 ll eluent. The recovery of dexniguldipine, M-1, and the internal standard was determined relative to the direct injection of the individual dissolved compounds.
Construction of calibration curves at up to 500 ng in tumor tissue
Dexniguldipine hydrochloride (B8509-035, batch 292-349) and B8909-008 (M-1, batch U1 29/071) were added to clean test tubes and the samples were evaporated under vacuum. Approximately 100 mg tumor tissue was added. Subsequently the procedure was carried out as outlined above.
Tumor model and in vivo experiments
Solid tumors of the CC531 colon adenocarcinoma tumor model were used according to a previously described method [7, 15] . Tumors of the intrinsic MDR cell line (CC531) were grown in donor Wag/Rij rats. Tumor particles of 6±7 mg were prepared and implanted under the renal capsule of both kidneys of the rats (subrenal capsule model). In all pharmacokinetics experiments, two particles were implanted per kidney. For each experiment (i.e., 5-, 24-, 48-h, and repeated administration) a new tumor batch was grown in donor rats. In all rats the right jugular vein was cannulated in the pharmacokinetics experiments for blood sampling at regular intervals. The experiments were started on day 1 with tumor implantation. The rats were cannulated, after full recovery, on day 3 or 4. During the experiments, diethyl ether anesthesia was applied. After termination of the experiments, rats were killed by cervical dislocation.
Pharmacokinetics experiments
An oral solution of 30 mg/kg dexniguldipine (1.5 ml/kg) was given through a thin metal oral cannula of 23 gauge on day 8 (single administration) or days 8±10 (repeated administration) after tumor implantation. Eight rats per treatment group were used. The solution consisted of an undiluted 2% dexniguldipine microemulsion (batch LSc 1974). The rats were given no food the night prior to the experiment. They had free access to drinking water. Blood samples were collected for up to 5 (5-h experiment), 24 (24-h experiment), or 48 (48-h experiment). The time points were 0, 10, 20, 30, 60, and 120 min and 4, 6, 10, 24, 32, and 48 h. In the 5-and 24-h experiments the sampling times ended at 5 and 24 h, respectively. Tumors and kidneys were collected immediately at the end of the sampling period. In the multiple-dose experiment, peak (2 h after drug intake) and trough (immediately prior to the next drug intake) blood samples were collected. Tumors and kidneys were collected at 5 h after administration of the ®nal dose on day 10. The area under the curve (AUC) was calculated using the lin-log trapezoidal method in all experiments. The Pearson correlation coecient was calculated were appropriate.
Results
Results of the analysis of dexniguldipine and M-1 plasma Calibration curves were linear up to the studied concentration of 2000 ng/ml. Correlation coecients were better than 0.999. The lower limit of quantitation (LLQ) of dexniguldipine and M-1 was 25 ng/ml. The betweenrun coecient of variation (%CV) at the LLQ was 15.1% for dexniguldipine and 24.7% for M-1. At almost all concentrations higher than the LLQ the %CV was around 5% or lower.
Results of the tumor-tissue extraction
Calibration curves were linear up to the studied concentration of 500 ng. The correlation coecients were >0.999. The LLQ of dexniguldipine and M-1 in tumor and renal tissue was 25 ng/g.
Pharmacokinetic experiments
In the 5-h experiment, seven of the eight rats were evaluable for plasma kinetics of dexniguldipine and M-1 and all rats were evaluable for tumor-and renal-tissue uptake. The plasma AUCs determined for the 48-h experiment are given in Fig. 1 . The AUC data are summarized in Table 1 . The AUC of M-1 was always lower than that of the parent drug ( Table 1 ). The concentration-time curves generated for the 48-h experiment reveal that the plasma concentration at 48 h could be determined in only one of the rats. In almost all rats the concentration-time curves could be determined at up to 32 h after administration. The AUC 0±48 h was calculated up to the latest measurable data point. The mean plasma concentration-time pro®les obtained for the 24-and 48-h experiments were superimposable, which illustrates that the pharmacokinetics are reproducible (Fig. 2) .
In the repeated-administration experiment, only limited plasma-kinetics data became available. Three cannulas became plugged and one rat was killed on day 1 of the 3-day experiment because of toxicity (reduced muscle tone, pilo erection, low blood pressure). The limited plasma-concentration data do not show major dierences in the kinetics determined on days 1, 2, and 3.
The tumor concentrations of dexniguldipine and M-1 measured in the outlined experiments are given in Table 2 . The concentrations of M-1 were substantially lower than those of the parent drug.
The concentrations of dexniguldipine were higher in renal tissue than in tumor tissue (Table 2) . Also, the M1 concentrations in renal tissue were on the order of 30% of the dexniguldipine concentrations, which resembles the relationship found in tumor tissue (data not shown). a The AUC data (n = 7) were calculated in all experiments up to the latest measured time point. In the 48-h experiment the AUC was determined up to the latest measurable concentration, which was detected at 31.7 h in all except one rat (11.2 h in rat 6) The order of magnitude of the renal concentrations recorded in the individual experiments was the same as that found in tumor tissue. The decline in the plasma concentration-time curves generated for the 24-and 48-h experiments paralleled the decline in the tumor-tissue concentrations of dexniguldipine, which illustrates the close relationship between the plasma kinetics and the tumor kinetics of dexniguldipine (Fig. 2) . In this ®gure the tumor concentrations measured in the 5-, 24-; and 48-h experiments were combined for the construction of a concentration-time curve. Furthermore, high correlation coecients were found between the tumor-tissue concentrations measured at the end of the experiment and the plasma AUC values obtained in the 5-(R=0.98, n=7) and 24-h experiments (R=0.84, n=7; Fig. 3) . The relationship between the tumor-tissue concentration and AUC 0±48 was not calculated because the AUC 0±48 value could not be determined in most of the rats, as is outlined above. In addition, high correlation coecients were found between tumor-and renal-tissue concentrations in all experiments (R values of at least 0.92). The tumor weights recorded in the four experiments varied and were 63 19 (5 h), 57 15 (24 h), 131 42 (48 h), and 81 29 mg (repeated administration).
Discussion
The present data describe the plasma, tumor, and renaltissue kinetics of dexniguldipine and its metabolite M-1 after single or repeated oral administration of 30 mg/kg dexniguldipine to tumor-bearing Wag/Rij rats. The concentrations of dexniguldipine and metabolite M-1 were determined in tumor tissue at 5, 24, and 48 h to evaluate the uptake kinetics in tumor tissue. In addition, the tumor concentrations were determined after 3 days of drug administration.
The plasma concentration-time curves generated for the 5-h experiment showed only a moderate decline. The kinetics in plasma were highly variable. In the 24-h experiment the AUC ranged from 1.15 to 4.31 lg h ml A1 . In addition, the time to maximal plasma concentration (T max ) was highly variable (Fig. 1) . Also, a study in humans has revealed that the pharmacokinetics are highly variable [14] . The elimination phase in the 48-h experiment was not long enough to enable calculation of the total AUC.
In the experiment involving repeated administration, limited plasma data became available due to plugging of three of the cannulas during the experiment. The plasma-concentration data recorded for the four evaluable rats revealed that the concentrations did not further increase after 2 days of dosing, indicating that nearsteady state had been reached. The administration once daily of 30 mg/kg dexniguldipine for 3 subsequent days was feasible except in one rat. No signi®cant cumulative toxicity in the remaining animals was observed. A previous pilot experiment revealed that this dose was the highest feasible dose upon repeated administration in this model (data not shown).
The tumor concentrations of dexniguldipine and M-1 also showed wide variation ( Table 2 ). It is unlikely that this variation would be due to dierences in the distribution kinetics of dexniguldipine, considering the high degrees of correlation found between AUC values and tumor concentrations of dexniguldipine. The concentrations of the parent drug and M-1 were highest after repeated administration of the former. The high degrees of correlation found between plasma and tumor-tissue concentrations enable the prediction of tumor concentrations using plasma samples in this in vivo model. The high variability of the plasma concentrations may be attributable to variation between rats in the bioavailability of dexniguldipine.
High degrees of correlation were found between tumor-and renal-tissue concentrations of dexniguldipine. The renal-tissue concentrations were always a factor of 1.5±4 higher than the tumor-tissue concentrations, depending on the sampling time (Table 2) . Dexniguldipine is a dihydropyridine derivative. This class of drugs is known to be extensively distributed in tissue. Dierences in lipophilicity between tissues, e.g., renal and tumor tissue, may therefore contribute to the observation of dierences in tissue concentration after exposure to dexniguldipine, in particular at steady state. The ratio of dexniguldipine to M1 was constant in all experiments.
The tumor weights showed variation between the experiments. The mean tumor weight measured in the 48-h experiment was clearly higher than that measured in the other experiments, which may have been due to tumor-batch dierences. As a consequence, tumor growth-inhibition experiments should be carried out using the same tumor batch.
The in vitro results reported for the MDR-modifying eect of dexniguldipine revealed that dexniguldipine was highly active at a concentration as low as 50 ng/ml [16] . In that experiment the same CC531 cell line was used. It is hazardous to extrapolate the results of in vitro studies to in vivo tumor models. However, considering the very high tumor-tissue concentrations of dexniguldipine measured in vivo, it may be anticipated that these concentrations are high enough to reverse MDR in vivo. Results of the pharmacodynamics study of dexniguldipine and epidoxorubicin in this model reveal a moderately but signi®cantly synergistic antitumor eect [16] .
In the present study, high concentrations were achieved in intrinsically MDR solid-tumor tissue implanted under the renal capsule of rats after single and multiple oral dosing of the MDR-modifying drug dexniguldipine. In addition, the high degrees of correlation found between plasma and tumor-tissue concentrations enable the prediction of tumor concentrations in this model by simple measurement of plasma concentrations.
